Synopsis
S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals October 2005 This guidance describes a nonclinical testing strategy for assessing the potential of a test substance to delay ventricular repolarization.
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at FDA: drugs ↗
